Medicine
Velphoro 250 mg chewable tablet
Velphoro 250 mg chewable tablet is a prescription medicine containing Ferric oxyhydroxide for oral use, marketed by Fresenius Medical Care Renal Therapies Group, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F).
Key facts
- Active ingredient (INN)
- Ferric oxyhydroxide
- Brand
- Velphoro
- Strength
- 250 mg
- Dosage form
- Chewable tablet
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Fresenius Medical Care Renal Therapies Group
- Manufacturer
- Fresenius Medical Care Renal Therapies Group
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 27 November 2013
- Identifiers
- RxCUI 1484289, 1484296DailyMed set ID 237da26c-f38c-4faa-93ad-735e71c9d0c1NDC 49230-646Application NDA205109
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 90 tablet, chewable in 1 bottle | 49230-646-61 | Fresenius Medical Care Renal Therapies Group | 27 November 2013 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 27 November 2013 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ferric oxyhydroxide
Clinical summary
Ferric oxyhydroxide is a phosphate binder indicated for the control of serum phosphorus levels in adults and pediatric patients 6 years of age and older with chronic kidney disease (CKD) on dialysis. MedsAcross supplies Ferric oxyhydroxide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ferric oxyhydroxideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Velphoro prescribing information (Fresenius Medical Care Renal Therapies Group) · U.S. National Library of Medicine, DailyMed
Need Velphoro 250 mg chewable tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.